Imetelstat
Last Updated: 02/24/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 161 publications
Updates in low/intermediate-risk MDS.
Journal: Hematology. American Society of Hematology. Education Program
Published: December 05, 2025
US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 24, 2025
Outcomes with imetelstat in myelofibrosis: a systematic review and meta-analysis.
Journal: Leukemia & lymphoma
Published: October 15, 2025
Telomerase inhibitors - TMPyP4, BIBR 1532 and imetelstat - alter the adhesion potential of breast cancer MCF7 and MDA-MB-231 cells that leads to impaired ability to form spheroids.
Journal: Cell adhesion & migration
Published: October 14, 2025
Plain language summary of IMerge, a Phase 3 study of imetelstat versus placebo in people with lower-risk myelodysplastic syndromes and anemia.
Journal: Future oncology (London, England)
Published: October 13, 2025
Using imetelstat for lower-risk myelodysplastic syndromes.
Journal: Clinical advances in hematology & oncology : H&O
Published: October 06, 2025
Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS.
Journal: Blood cancer journal
Published: September 18, 2025
Myelodysplastic syndromes: Updates on Genomic Landscape, Molecular Subtypes, & Targeted Therapies.
Journal: Current hematologic malignancy reports
Published: August 25, 2025
Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study.
Journal: Haematologica
Published: August 21, 2025
Imetelstat: A First-in-Class Telomerase Inhibitor for the Treatment of Patients With Lower-Risk Myelodysplastic Syndromes and Anemia.
Journal: Journal of the advanced practitioner in oncology
Published: August 11, 2025
Recent progress in human telomerase structure and its therapeutic targeting.
Journal: Frontiers in molecular biosciences
Published: August 08, 2025
Management of Anemia in Lower-Risk Myelodysplastic Syndromes/Neoplasms With Novel Agents.
Journal: JCO oncology practice
Published: August 05, 2025
Last Updated: 02/24/2026